Last reviewed · How we verify
Dose 1 of glycopyrronium, 2.5% QD
Dose 1 of glycopyrronium, 2.5% QD is a Anticholinergic Small molecule drug developed by Journey Medical Corporation. It is currently in Phase 2 development for Treatment of glaucoma. Also known as: DRM04.
Glycopyrronium is an anticholinergic that works by blocking the action of acetylcholine at muscarinic receptors, leading to reduced salivation and sweating.
Glycopyrronium is an anticholinergic that works by blocking the action of acetylcholine at muscarinic receptors, leading to reduced salivation and sweating. Used for Treatment of glaucoma.
At a glance
| Generic name | Dose 1 of glycopyrronium, 2.5% QD |
|---|---|
| Also known as | DRM04 |
| Sponsor | Journey Medical Corporation |
| Drug class | Anticholinergic |
| Target | Muscarinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the muscarinic acetylcholine receptors, glycopyrronium decreases the parasympathetic nervous system's effect on the salivary and sweat glands, resulting in reduced secretions.
Approved indications
- Treatment of glaucoma
Common side effects
- Dry mouth
- Blurred vision
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dose 1 of glycopyrronium, 2.5% QD CI brief — competitive landscape report
- Dose 1 of glycopyrronium, 2.5% QD updates RSS · CI watch RSS
- Journey Medical Corporation portfolio CI
Frequently asked questions about Dose 1 of glycopyrronium, 2.5% QD
What is Dose 1 of glycopyrronium, 2.5% QD?
How does Dose 1 of glycopyrronium, 2.5% QD work?
What is Dose 1 of glycopyrronium, 2.5% QD used for?
Who makes Dose 1 of glycopyrronium, 2.5% QD?
Is Dose 1 of glycopyrronium, 2.5% QD also known as anything else?
What drug class is Dose 1 of glycopyrronium, 2.5% QD in?
What development phase is Dose 1 of glycopyrronium, 2.5% QD in?
What are the side effects of Dose 1 of glycopyrronium, 2.5% QD?
What does Dose 1 of glycopyrronium, 2.5% QD target?
Related
- Drug class: All Anticholinergic drugs
- Target: All drugs targeting Muscarinic acetylcholine receptors
- Manufacturer: Journey Medical Corporation — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Treatment of glaucoma
- Also known as: DRM04
- Compare: Dose 1 of glycopyrronium, 2.5% QD vs similar drugs
- Pricing: Dose 1 of glycopyrronium, 2.5% QD cost, discount & access